Lumigan and Conjunctivitis aggravated - a phase IV clinical study of FDA data

Summary:

Conjunctivitis aggravated is reported as a side effect among people who take Lumigan (bimatoprost), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Combigan, and have Intraocular pressure increased.

The phase IV clinical study analyzes which people have Conjunctivitis aggravated when taking Lumigan. It is created by eHealthMe based on reports of 20,141 people who have side effects when taking Lumigan from the FDA, and is updated regularly.

What is Lumigan?

Lumigan has active ingredients of bimatoprost. It is often used in glaucoma. eHealthMe is studying from 20,478 Lumigan users. Check the latest studies of Lumigan.

What is Conjunctivitis aggravated?

Conjunctivitis aggravated (infection of conjunctiva) is found to be associated with 1,048 drugs and 366 conditions by eHealthMe. Check the latest studies of Conjunctivitis aggravated.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

20,141 people reported to have side effects when taking Lumigan.
Among them, 73 people (0.36%) have Conjunctivitis aggravated.

Could Lumigan cause Conjunctivitis aggravated?

Among these 73 people:

How long have people been on Lumigan when they have Conjunctivitis aggravated? *

What is the gender of people who have Conjunctivitis aggravated when taking Lumigan? *

female: 83.1 %
male: 16.9 %

What is the age of people who have Conjunctivitis aggravated when taking Lumigan? *

What are other drugs people take besides Lumigan? *

What are other side effects people have besides Conjunctivitis aggravated? *

Ocular Hyperaemia (an abnormally large amount of blood in eye): 21 people, 28.77%
Lacrimation Increased: 11 people, 15.07%
Eye Irritation: 11 people, 15.07%
Eye Pain: 10 people, 13.70%
Vision Blurred: 9 people, 12.33%
Hypersensitivity: 9 people, 12.33%
Corneal Opacity (scarring or clouding of the cornea): 8 people, 10.96%
Eye Swelling: 8 people, 10.96%
Cough: 8 people, 10.96%
Fatigue (feeling of tiredness): 7 people, 9.59%

What are the existing conditions these people have? *

Intraocular Pressure Increased: 11 people, 15.07%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 5 people, 6.85%
Depression: 5 people, 6.85%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 5 people, 6.85%
Dry Eyes (lack of adequate tears): 4 people, 5.48%
Asthenopia (eyestrain-tiredness of the eyes caused by prolonged close work by a person with an uncorrected vision problem): 4 people, 5.48%
High Blood Cholesterol: 3 people, 4.11%
Pain: 3 people, 4.11%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 3 people, 4.11%
Intraocular Pressure: 3 people, 4.11%

* Approximation only. Some reports may have incomplete information.

Do you take Lumigan and have Conjunctivitis aggravated?

- Check whether Conjunctivitis aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lumigan:

Lumigan (20,478 reports)

Browse all side effects of Lumigan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Conjunctivitis aggravated:

Conjunctivitis aggravated (1,048 drugs)

Browse all the conditions that are associated with Conjunctivitis aggravated:

Conjunctivitis aggravated (366 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on bimatoprost (the active ingredients of Lumigan) and Lumigan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.